Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement

被引：0
|
作者：
Bedics, Gabor [1 ,2 ]
Csoka, Monika [3 ]
Reiniger, Lilla [1 ]
Varga, Edit [3 ]
Liptai, Zoltan [3 ]
Papp, Gergo [1 ]
Beko, Anna [1 ,2 ]
Cervi, Catherine [3 ]
Bodor, Csaba [1 ,2 ]
Scheich, Balint [1 ]
机构：
[1] Semmelweis Univ, Dept Pathol & Expt Canc Res, Ulloi Ut 26, H-1085 Budapest, Hungary
[2] Semmelweis Univ, Dept Pathol & Expt Canc Res, HCEMM SU Mol Oncohematol Res Grp, Ulloi Ut 26, H-1085 Budapest, Hungary
[3] Semmelweis Univ, Dept Pediat 2, Tuzolto U 7-9, H-1094 Budapest, Hungary
来源：
ACTA NEUROPATHOLOGICA | 2023年 / 145卷 / 01期
基金：
欧盟地平线“2020”;
关键词：
D O I：
10.1007/s00401-022-02520-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：153 / 156
页数：4
相关论文
共 38 条
  • [31] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Drilon, Alexander
    Barlesi, Fabrice
    De Braud, Filippo
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Siena, Salvatore
    Krebs, Matthew G.
    Lin, Chia-Chi
    John, Tom
    Tan, Daniel S. W.
    Seto, Takashi
    Dziadziuszko, Rafal
    Arkenau, Hendrick-Tobias
    Rolfo, Christian
    Wolf, Juergen
    Ye, Chenglin
    Riehl, Todd
    Eng, Susan
    Doebele, Robert C.
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
    Paz-Ares, L.
    Barlesi, F.
    Siena, S.
    Ahn, M-J
    Drilon, A.
    Conley, A.
    Rolfo, C.
    Wolf, J.
    Seto, T.
    Doebele, R.
    Kapre, A.
    Chen, D.
    McCallum, S.
    Osborne, S.
    Demetri, G.
    ESMO OPEN, 2021, 6 (03)
  • [33] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    de Braud, F.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B.
    Huang, X.
    Osborne, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    De Braud, F. G. M.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B. P.
    Huang, X.
    Ye, C.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 609 - 609
  • [35] Novel genome-wide significant germline genetic variants associated with venous thrombo-embolism (VTE) and arterial embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC).
    Khan, Sam
    Jimenez, Beatriz
    Hueniken, Katrina
    Hou, Tianzhichao
    Patel, Devalben
    Stockley, Tracy
    Tsao, Ming-Sound
    Zer, Alona
    Moskovitz, Mor
    Rosenberg, Yehuda
    Bradbury, Penelope Ann
    Eng, Lawson
    Leighl, Natasha B.
    Sacher, Adrian G.
    Liu, Geoffrey
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Entrectinib in Locally Advanced / Metastatic ROS1 and NTRK Fusion-Positive (NTRK plus ) Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Springfeld, Christoph
    de Braude, Filippo
    Siena, Salvatore
    Barlesi, Fabrice
    Drilon, Alexander
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Doebele, Robert C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
  • [37] Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay
    Rodriguez-Antolin, Carlos
    Rosas-Alonso, Rocio
    Cruz, Patricia
    Higuera, Oliver
    Sanchez-Cabrero, Dario
    Esteban-Rodriguez, Isabel
    Pelaez-Garcia, Alberto
    Fernandez Montano, Victoria Eugenia
    Rodriguez-Jimenez, Carmen
    Ibanez de Caceres, Inmaculada
    de Castro, Javier
    ONCOLOGIST, 2021, 26 (06): : E908 - E912
  • [38] Phase 2 Trial of High-Dose Rituximab With High-Dose Cytarabine Mobilization Therapy and High-Dose Thiotepa, Busulfan, and Cyclophosphamide Autologous Stem Cell Transplantation in Patients With Central Nervous System Involvement by Non-Hodgkin Lymphoma
    Chen, Yi-Bin
    Batchelor, Tracy
    Li, Shuli
    Hochberg, Ephraim
    Brezina, Mark
    Jones, Sooae
    Del Rio, Candice
    Curtis, Morgan
    Ballen, Karen K.
    Barnes, Jeffrey
    Chi, Andrew S.
    Dietrich, Jorg
    Driscoll, Jessica
    Gertsner, Elizabeth R.
    Hochberg, Fred
    LaCasce, Ann S.
    McAfee, Steven L.
    Spitzer, Thomas R.
    Nayak, Lakshmi
    Armand, Philippe
    CANCER, 2015, 121 (02) : 226 - 233
1234